Tag: KRAS mutation
-
R-nuucell Selected by EP PerMed to Validate Cancer Therapy
R-nuucell Joins EP PerMed to Validate a Novel Cancer Therapy A Portuguese biotech startup is taking a significant step forward in the fight against aggressive cancers. R-nuucell has been selected as one of eight European companies to participate in the EP PerMed program, a six-month initiative funded by the European Union aimed at validating promising…